BR112022003130A2 - Compostos inovadores - Google Patents

Compostos inovadores

Info

Publication number
BR112022003130A2
BR112022003130A2 BR112022003130A BR112022003130A BR112022003130A2 BR 112022003130 A2 BR112022003130 A2 BR 112022003130A2 BR 112022003130 A BR112022003130 A BR 112022003130A BR 112022003130 A BR112022003130 A BR 112022003130A BR 112022003130 A2 BR112022003130 A2 BR 112022003130A2
Authority
BR
Brazil
Prior art keywords
compounds
innovative
innovative compounds
diseases
sarcoidosis
Prior art date
Application number
BR112022003130A
Other languages
English (en)
Inventor
Bengt Ohlsson
Tomas Fex
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of BR112022003130A2 publication Critical patent/BR112022003130A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos inovadores. é fornecido neste documento um composto de fórmula i, em que r1, r2, r3 y1, y2, y3, y4, r4, r5 e r6 são como aqui definidos, compostos esses que são úteis no tratamento de doenças autoimunes e/ou fibróticas, incluindo doenças pulmonares intersticiais, tais como fibrose pulmonar idiopática e sarcoidose.
BR112022003130A 2019-09-20 2020-09-18 Compostos inovadores BR112022003130A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201913603A GB201913603D0 (en) 2019-09-20 2019-09-20 New compounds
PCT/GB2020/052261 WO2021053344A1 (en) 2019-09-20 2020-09-18 New compounds

Publications (1)

Publication Number Publication Date
BR112022003130A2 true BR112022003130A2 (pt) 2022-05-17

Family

ID=68425648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003130A BR112022003130A2 (pt) 2019-09-20 2020-09-18 Compostos inovadores

Country Status (14)

Country Link
US (1) US20220388994A1 (pt)
EP (1) EP4031240A1 (pt)
JP (1) JP2022549086A (pt)
KR (1) KR20220101071A (pt)
CN (1) CN114786774A (pt)
AU (1) AU2020351301A1 (pt)
BR (1) BR112022003130A2 (pt)
CA (1) CA3152218A1 (pt)
CL (1) CL2022000656A1 (pt)
CO (1) CO2022003091A2 (pt)
GB (1) GB201913603D0 (pt)
IL (1) IL291172A (pt)
MX (1) MX2022003286A (pt)
WO (1) WO2021053344A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202013721D0 (en) * 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds
WO2022200785A1 (en) * 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
WO2023281271A1 (en) * 2021-07-09 2023-01-12 Vicore Pharma Ab New selective angiotensin ii compounds
WO2023193733A1 (zh) * 2022-04-06 2023-10-12 武汉人福创新药物研发中心有限公司 一种at2r激动剂
WO2024133942A1 (en) 2022-12-22 2024-06-27 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
WO2024149712A1 (en) * 2023-01-09 2024-07-18 Vicore Pharma Ab Selective angiotensin ii compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
US20170266164A1 (en) 2014-12-12 2017-09-21 Vicore Pharma Ab New methods and uses
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
MX2017010993A (es) 2015-03-02 2018-04-11 Vicore Pharma Ab Agonista del receptor de angiotensina ii para tratar la fibrosis pulmonar.
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy

Also Published As

Publication number Publication date
CN114786774A (zh) 2022-07-22
MX2022003286A (es) 2022-04-12
CA3152218A1 (en) 2021-03-25
EP4031240A1 (en) 2022-07-27
IL291172A (en) 2022-05-01
CO2022003091A2 (es) 2022-04-19
JP2022549086A (ja) 2022-11-24
CL2022000656A1 (es) 2022-11-04
KR20220101071A (ko) 2022-07-19
US20220388994A1 (en) 2022-12-08
GB201913603D0 (en) 2019-11-06
AU2020351301A1 (en) 2022-03-17
WO2021053344A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
BR112022003130A2 (pt) Compostos inovadores
PH12019501034A1 (en) New anthelmintic quinoline-3-carboxamide derivatives
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
PH12021551167A1 (en) New heterocyclic compounds
MX2017016482A (es) Lactamas biciclicas y metodos de uso de las mismas.
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
PH12017501279A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
NZ732657A (en) Picolinamides with fungicidal activity and other related compounds
ZA201904522B (en) Heterocyclic inhibitors of mct4
EA201891409A1 (ru) Бензамидные соединения и их применение в качестве гербицидов
MX361606B (es) Compuestos antihelmínticos.
CY1120295T1 (el) Υποκατεστημενα θειαζολια η οξαζολια ως ανταγωνιστες υποδοχεα ρ2χ7
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
PH12017500095A1 (en) Imidazopyridazine compounds
PH12018501575A1 (en) Indolinones compounds and their use in the treatment of fibrotic diseases
MX2021001565A (es) Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad).
CL2023000580A1 (es) Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii
BR112015006560A2 (pt) 3-heteroaril-isoxazolina-5-carboxamidas e 3-heteroaril-isoxazolina-5-tioamidas com atividade herbicida e fungicida
TW201613896A (en) Novel 2,5-substituted pyrimidines
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
PE20180247A1 (es) Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap)
MX2021001034A (es) Derivados novedosos de piridina 3,5-disustituida y piridazina 3,5-disustituida y uso farmaceutico de los mismos.
MX2020000576A (es) Compuestos quimicos.
JOP20180029A1 (ar) مركب حلقي غير متجانس
PH12019501171A1 (en) Pyrido [3, 4-d] pyrimidine derivative and pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]